|Bid||282.60 x 0|
|Ask||283.00 x 0|
|Day's Range||279.30 - 284.30|
|52 Week Range||252.30 - 477.70|
|Beta (3Y Monthly)||1.00|
|PE Ratio (TTM)||14.38|
|Earnings Date||May 8, 2019|
|Forward Dividend & Yield||12.00 (4.24%)|
|1y Target Est||302.29|
Valby, Denmark and Tokyo, Japan, 14 February 2019 H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce today that data from two global Phase III clinical trials evaluating the safety and efficacy of brexpiprazole for the treatment of patients with manic episodes associated with bipolar I disorder did not meet the primary endpoint. The duration of the randomized phase of each trial was 3 weeks.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Many investors are still learning about theRead More...
European shares hit nine-week highs on Tuesday, as a recovery in banks, gains in oil stocks on stronger crude prices and a solid update from BP helped offset some disappointing updates including from Apple supplier AMS. "I feel that markets in general are looking for a reason to move up", said James Bateman, chief investment officer at Fidelity International.
Financial report for the period 1 January to 31 December 2018 Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018.
H. Lundbeck A/S (Lundbeck) today announced that Dr. Johan Luthman has been appointed Executive Vice President and Head of Research & Development in Lundbeck. Johan will assume his new role and join the Executive Management on 1 March 2019 and brings approximately 28 years of experience in pharmaceutical R&D. Johan has been exposed to R&D management from companies such as Eisai, Merck & Co and AstraZeneca and has taken through development of small molecules and biopharmaceuticals (mAb and protein therapeutics) programs in neuroscience (neurology, psychiatry, pain and ophthalmology), metabolic diseases and immunology & inflammation areas.
Looking at H. Lundbeck A/S's (CPH:LUN) earnings update in September 2018, analyst consensus outlook seem bearish, as a -9.0% fall in profits is expected in the upcoming year against the Read More...
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today the achievement of positive clinical results (in intention-to-treat population) as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score change from baseline compared to placebo, when brexpiprazole and sertraline was given as combination treatment (p
Valby, Nov. 20, 2018 (GLOBE NEWSWIRE) -- - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 32,870 as a consequence of the exercise of employee warrants. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 800 shares at DKK 121 and 5,774 shares at DKK 113. Proceeds to the company are DKK 749,262 (approximately USD 0.114 million).
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we’ll show how H Lundbeck A/S’s (CPH:LUN) Read More...
If you want to know who really controls H Lundbeck A/S (CPH:LUN), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more Read More...
Symptoms of nOH may affect approximately one in five people with Parkinson’s Disease
A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. Historically, H Lundbeck A/S (CPH:LUN) has beenRead More...
This article is intended for those of you who are at the beginning of your investing journey and want to learn about Return on Equity using a real-life example. HRead More...
By Julien Ponthus LONDON (Reuters) - European shares dipped on Wednesday as poor corporate earnings in the pharmaceutical sector weighed on sentiment already soured by trade tensions, with Washington preparing ...
Based on H Lundbeck A/S’s (CPH:LUN) earnings update in March 2018, the consensus outlook from analysts appear fairly confident, as a 17.82% increase in profits is expected in the upcomingRead More...